Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20266 Citations
Setmelanotide (IMCIVREE) is the only FDA-approved MC4R agonist for rare genetic obesity. Phase 3 data showed 25.6% mean weight loss in POMC-deficient patients at 52 weeks. Strict genetic testing required; does not work for common polygenic obesity. Prescription only, administered as a daily injection.
1mg · Daily
Summary: Add 2mL BAC water to your 10mg vial. Draw to 20.0 units on a U-100 syringe for a 1mg dose. This vial will last 10 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mg | Daily |
| Moderate | 2mg | Daily |
| Aggressive | 3mg | Daily |
No reconstitution needed. IMCIVREE ships as a ready-to-inject 10 mg/mL solution in multi-dose vials. That's one less variable to manage. If you receive a lyophilized powder claiming to be setmelanotide, it is not the FDA-approved product. Syringe math for the 10 mg/mL vial using a U-100 insulin syringe: 1 mg equals 10 units (0.1 mL), 2 mg equals 20 units (0.2 mL), 3 mg equals 30 units (0.3 mL). Each vial contains 10 mg total. Inject in the morning. The 11-hour half-life means drug levels peak around 8 hours post-dose. Morning dosing aligns appetite suppression with daytime eating patterns. Store unopened vials at 2 to 8 degrees Celsius. Once in use, the vial can stay at room temperature (up to 30 degrees Celsius) for up to 30 days. Discard after 30 days regardless of remaining volume. This drug requires confirmed genetic testing before prescribing. Rhythm Pharmaceuticals provides free genetic testing through their IMCIVREE support program. You can't skip that step; setmelanotide won't help without a confirmed pathogenic variant.
Dosing based on IMCIVREE FDA Prescribing Information (2024) — 10 published references.View all sources →
Cross-check your Setmelanotide reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Setmelanotide (IMCIVREE) is the only FDA-approved MC4R agonist for rare genetic obesity. Phase 3 data showed 25.6% mean weight loss in POMC-deficient patients at 52 weeks. Strict genetic testing required; does not work for common polygenic obesity. Prescription only, administered as a daily injection.